The firm is conducting validation studies on its lung cancer test and continues to anticipate commercializing it in the second half of this year.
The company will use the funds to expand its operations across the US, Europe, and Asia as well as to support the launch of new single-cell protein assays.
Arcis Biotechnology and Andrew Alliance will comarket their respective technologies for automated nucleic acid stabilization and preparation.
The four-year loan will be used to develop molecular diagnostic assays for the firm's two test systems, Amplidiag and Novodiag.
Roche said that the test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting resistance to the antibiotics rifampicin and isoniazid.
The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
SensID specializes in the development, manufacture, and marketing or reference materials and quality controls for DNA-based diagnostics.
The PCR-based test is designed to detect 47 antibiotic resistance genes in less than three hours from bacterial isolates to help guide treatment decisions.
The firm said its growth was driven in part by increasing sales volumes of its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.
The study aims to identify individuals with mutations in Parkinson's disease-associated genes for further analysis.
The firm sold 4.31 million shares after the underwriters fully exercised their options to purchase 562,500 shares at the offering price of $21 per share.
A pair of new studies evaluated the effectiveness of cytologic and HPV-based testing approaches at varied screening intervals for identifying women at risk of cervical cancer.
Last week, GenomeWeb's readers were most interested in two studies that showed that ctDNA can offer clinically useful insights into colorectal cancer.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
A speaker at this year's Biology of Genomes meeting discussed marrying genomics approaches such as CRISPR and single-cell sequencing to study disease causality.
Baylor Genetics will be King Faisal Specialist Hospital International's exclusive lab partner for all genetic testing and precision medicine applications.
The company also announced that its board of directors has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock.
Based on allele fragment sizes and mutational signatures, Europeans may have had shorter generation times than other populations, a Biology of Genomes speaker said.
The embattled company saw its net loss narrow during the first quarter, in part due to a new policy of giving away fewer nonreimbursed GPS Cancer and Liquid GPA molecular test orders than in the past.
The liquid biopsy firm beat analyst estimates on the top and bottom lines and raised full-year revenue guidance to $145 to $150 million.
The company's first quarter revenues were driven by sales of its noninvasive prenatal screening and carrier screening tests.
While the company's product and product-related revenues rose 54 percent, its collaborative development program revenues fell 78 percent.
The company reported total revenues of $27.7 million, with growth in its consumables business but a drop in instrument revenues from the prior year's first quarter.
University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.
A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.
Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.
In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.